Evidence map›Paper›PMID 26497740›Full record

ArticleBMC cancer2015

The NF-κB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription.

Priscilla S Simon, Sarah K Sharman, Chunwan Lu, Dafeng Yang, Amy V Paschall, Sidhartha S Tulachan, Kebin Liu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Priscilla S SimonDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Predd@gru.edu.
Sarah K SharmanDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Ssharman@gru.edu.
Chunwan LuDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Clu@gru.edu.
Dafeng YangDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Dyang@gru.edu.
Amy V PaschallDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Apaschall@gru.edu.
Sidhartha S TulachanMedicine, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Stulachan@gru.edu.
Kebin LiuDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA. Kliu@gru.edu.
Augusta University · US

Funding

Role of IRF8 in Tumor Rejection and SuppressionR01CA133085 · NCI · AUGUSTA UNIVERSITY · PI LIU, KEBIN · 2008 to 2019
$2.9M
Role of NF-kB in Fas-mediated Apoptosis and Tumor SuppressionR01CA182518 · NCI · AUGUSTA UNIVERSITY · PI LIU, KEBIN · 2014 to 2018
$1.6M
Function of Verticillin A in Suppression of MDSC and CRC Stem CellsI01BX001962 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI LIU, KEBIN · 2014 to 2017
–
6 · The paper itself

Abstract

backgroundInducible nitric oxide synthase (iNOS) metabolizes L-arginine to produce nitric oxide (NO) which was originally identified in myeloid cells as a host defense mechanism against pathogens. Recent studies, however, have revealed that iNOS is often induced in tumor cells and myeloid cells in the tumor microenvironment. Compelling experimental data have shown that iNOS promotes tumor development in certain cellular context and suppresses tumor development in other cellular conditions. The molecular mechanisms underlying these contrasting functions of iNOS is unknown. Because iNOS is often induced by inflammatory signals, it is therefore likely that these contrasting functions of iNOS could be controlled by the inflammatory signaling pathways, which remains to be determined.

methodsiNOS is expressed in colon carcinoma and myeloid cells in the tumor microenvironment. Colon carcinoma and myeloid cell lines were used to elucidate the molecular mechanisms underlying iNOS expression. Chromatin immunoprecipitation and electrophoretic mobility shift assay were used to determine the IFNγ-activated pSTAT1 and NF-κB association with the chromatin DNA of the nos2 promoter.

resultsWe show here that iNOS is dramatically up-regulated in inflammed human colon tissues and in human colon carcinoma as compared to normal colon tissue. iNOS is expressed in either the colon carcinoma cells or immune cells within the tumor microenvironment. On the molecular level, the proinflammatory IFNγ and NF-κB signals induce iNOS expression in human colon cancer cells. We further demonstrate that NF-κB directly binds to the NOS2 promoter to regulate iNOS expression. Although neither the IFNγ signaling pathway nor the NF-κB signaling pathway alone is sufficient to induce iNOS expression in myeloid cells, IFNγ and NF-κB synergistically induce iNOS expression in myeloid cells. Furthermore, we determine that IFNγ up-regulates IRF8 expression to augment NF-κB induction of iNOS expression. More interestingly, we observed that the p65/p65 and p50/p50 homodimers, not the canonical p65/p50 heterodimer, directly binds to the nos2 promoter to regulate iNOS expression in myeloid cells.

conclusionsIFNγ-induced IRF8 acts in concert with NF-κB to regulate iNOS expression in both colon carcinoma and myeloid cells. In myeloid cells, the NF-κB complexes that bind to the nos2 promoter are p65/p65 and p50/p50 homodimers.

Indexed as

AnimalsCell Line, TumorColonColonic NeoplasmsHumansInterferon-gammaInterferon Regulatory Factor-8Interferon Regulatory FactorsMiceMyeloid CellsNF-kappa B p50 SubunitNitric Oxide Synthase Type IIPromoter Regions, GeneticTranscription Factor RelATumor MicroenvironmentInterferon-gammaInterferon Regulatory Factor-8Interferon Regulatory FactorsNF-kappa B p50 SubunitNitric Oxide Synthase Type IINOS2 protein, humanTranscription Factor RelA

Identifiers

PMID26497740
PMCPMC4619452
OpenAlexW1872482369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.